Funding for this research was provided by:
Worldwide Cancer Research (19-0059, 19-0059)
Cancer Research UK (A26892, A20183, A26892)
Article History
First Online: 5 August 2021
Competing interests
: EWT is a director and shareholder at Myricx Pharma Ltd; all other authors declare no competing interests.